摘要
目的:探究甲状腺功能亢进症(甲亢)行丙硫氧嘧啶和甲巯咪唑的临床效果及不良事件发生率。方法:择取2016年1月-2017年1月收治的60例甲亢患者临床资料进行分析,将行丙硫氧嘧啶治疗者设为对照组(30例),行甲巯咪唑治疗者设为研究组(30例),比较两组甲状腺功能、肝功能指标水平及不良事件发生率。结果:研究组与对照组治疗后甲状腺功能指标TSH、FT4、FT3水平均优于治疗前(P<0.05),且治疗后两组各指标水平比较,差异无统计学意义(P>0.05);研究组肝功能损伤发生率显著低于对照组(P<0.05),两组白细胞减少、皮肤瘙痒发生率比较,差异均无统计学意义(P>0.05);两组治疗后ALT、GGT水平均高于治疗前(P<0.05),且治疗后对照组ALT(47.27±5.04)U/L、GGT(42.26±2.15)U/L水平高于研究组(P<0.05)。结论:甲亢患者采用丙硫氧嘧啶或甲巯咪唑均具良好疗效,但丙硫氧嘧啶治疗者肝功能损伤性较大,因而临床治疗过程中应定期检查患者肝功能。
Objective:To investigate the clinical efficacy and incidence of adverse events of Propylthiouracil and Methimazole in patients with hyperthyroidism.Method:The clinical data of 60 patients with hyperthyroidism admitted from January 2016 to January 2017 were selected for analysis.The patients receiving Propylthiouracil were selected as the control group(30 cases).The patients treated with Methimazole were designated as the study group(30 cases).Compared the thyroid function,liver function indicators and the incidence of adverse events of the two groups.Result:The levels of thyroid function such as TSH、FT4、FT3 lever after treatment in the study group and control group were better than those before treatment(P<0.05),and there were no significant differences in the level of the indexes between the two groups after treatment(P>0.05).The incidence of liver function damage in the study group was significantly lower than that of the control group(P<0.05),and there were no significant differences of leukopenia and pruritus incidence(P>0.05).After treatment,the ALT and GGT levels in the two groups were higher than those before treatment(P<0.05);and the levels of ALT of(47.27±5.04)U/L,GGT of(42.26±2.15)U/L were significantly higher in the control group than those in the study group(P<0.05).Conclusion:Patients with hyperthyroidism can have good efficacy with both Propylthiouracil or Methimazole,but Propylthiouracil has a greater impairment of liver function.Therefore,liver function should be checked regularly during clinical treatment.
作者
黄素平
HUANG Suping(Qianjiang City Hospital,Qianjiang 433199,China)
出处
《中外医学研究》
2018年第22期10-12,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
